Hepatic Decompensation in Antiretroviral-Treated Patients Co-Infected With HIV and Hepatitis C Virus Compared With Hepatitis C Virus-Monoinfected Patients A Cohort Study

Vincent Lo Re, University of Pennsylvania
Michael J. Kallan, University of Pennsylvania
Janet P. Tate, VA Connecticut Healthcare System
A. Russell Localio, University of Pennsylvania
Joseph K. Lim, University of Pennsylvania
Matthew Bidwell Goetz, David Geffen School of Medicine at UCLA
Marina B. Klein, Baylor College of Medicine
David Rimland, Emory University
Maria C. Rodriguez-Barradas, Baylor College of Medicine
Adeel A. Butt, University of Pittsburgh School of Medicine

Only first 10 authors above; see publication for full author list.

**Journal Title:** Annals of Internal Medicine

**Volume:** Volume 160, Number 6

**Publisher:** American College of Physicians | 2014-03-18, Pages 369-379

**Type of Work:** Article | Post-print: After Peer Review

**Publisher DOI:** 10.7326/M13-1829

**Permanent URL:** [https://pid.emory.edu/ark:/25593/vh9nf](https://pid.emory.edu/ark:/25593/vh9nf)

Final published version: [http://dx.doi.org/10.7326/M13-1829](http://dx.doi.org/10.7326/M13-1829)

**Copyright information:**

© 2014 American College of Physicians.

Accessed December 3, 2022 10:29 PM EST
Hepatic Decompensation in Antiretroviral-Treated HIV/Hepatitis C-Coinfected Compared to Hepatitis C-Monoinfected Patients: A Cohort Study

Vincent Lo Re III, MD, MSCE a,b,c, Michael J. Kallan, MS b, Janet P. Tate, ScD d,e, A. Russell Localio, PhD b, Joseph K. Lim, MD d,e, Matthew Bidwell Goetz, MD f, Marina B. Klein, MD, MSc g, David Rimland, MD h, Maria C. Rodriguez-Barradas, MD i, Adeel A. Butt, MD, MS j, Cynthia L. Gibert, MD, MSc k, Sheldon T. Brown, MD l, Lesley Park, MPH e,m, Robert Dubrow, MD, PhD e,m, K. Rajender Reddy, MD n, Jay R. Kostman, MD a, Brian L. Strom, MD, MPH a,b,n, and Amy C. Justice, MD, PhD d,e

a Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
b Department of Biostatistics and Epidemiology and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
c Medical Service, Philadelphia VA Medical Center, Philadelphia, PA
d VA Connecticut Healthcare System, West Haven, CT
e Yale University School of Medicine, New Haven, CT
f VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at UCLA, Los Angeles, CA
g Chronic Viral Illness Service, McGill University Health Centre, Montreal, Canada
h Atlanta VA Medical Center and Emory University School of Medicine, Atlanta, GA
i Infectious Diseases Section, Michael E. DeBakey VA Medical Center and Department of Medicine, Baylor College of Medicine, Houston, TX
j University of Pittsburgh School of Medicine, Pittsburgh, PA and Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates
k Washington DC VA Medical Center and George Washington University Medical Center, Washington, DC
l James J. Peters VA Medical Center and Mt. Sinai School of Medicine, New York, NY

Address Correspondence to: V. Lo Re III, M.D., M.S.C.E., Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 836 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021, vincentl@mail.med.upenn.edu, Tel: 215-573-5964, Fax: 215-349-5111.

Potential conflicts of interest: None to report.

Publisher’s Disclaimer: Disclaimer: The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government.

Abstract

Background—The incidence and determinants of hepatic decompensation have been incompletely examined among HIV/hepatitis C virus (HCV)-coinfected patients in the antiretroviral therapy (ART) era, and few studies have compared rates of outcomes to those of patients with chronic HCV alone.

Objectives—To compare the incidence of hepatic decompensation between antiretroviral-treated HIV/HCV-coinfected and HCV-monoinfected patients, and evaluate factors associated with decompensation among coinfected patients on ART.

Design—Retrospective cohort study.

Setting—Veterans Health Administration.

Patients—4,280 HIV/HCV-coinfected patients who initiated ART and 6,079 HCV-monoinfected patients receiving care between 1997 and 2010. All patients had detectable HCV RNA and were HCV treatment-naïve.

Measurements—Incident hepatic decompensation, determined by diagnoses of ascites, spontaneous bacterial peritonitis, or esophageal variceal hemorrhage.

Results—The incidence of hepatic decompensation was greater among coinfected than monoinfected patients (at 10 years: 7.4% versus 4.8%; p<0.001). Compared to HCV-monoinfected patients, antiretroviral-treated HIV/HCV-coinfected patients had a higher rate of hepatic decompensation (hazard ratio [HR] accounting for competing risks, 1.56 [95% confidence interval (CI), 1.31–1.86]). Coinfected patients who maintained HIV RNA levels <1,000 copies/mL still had higher rates of decompensation than HCV-monoinfected patients (HR, 1.44 [95% CI, 1.05–1.99]). Baseline advanced hepatic fibrosis (FIB-4 >3.25; HR, 5.45 [95% CI, 3.79–7.84]), baseline hemoglobin <10 g/dL (HR, 2.24 [CI, 1.20–4.20]), diabetes mellitus (HR, 1.88 [95% CI, 1.38–2.56]), and non-black race (HR, 2.12 [95% CI, 1.65–2.72]) were each associated with higher rates of decompensation among coinfected patients on ART.

Limitations—Observational study of predominantly male patients.

Conclusions—Despite ART, HIV/HCV-coinfected patients had higher rates of hepatic decompensation than HCV-monoinfected individuals. Rates of decompensation were higher for coinfected patients with advanced liver fibrosis, severe anemia, diabetes, and non-black race.

Keywords
hepatic decompensation; end-stage liver disease; HIV/HCV coinfection; HIV; hepatitis C

INTRODUCTION

Coinfection with chronic hepatitis C virus (HCV) occurs in 10–30% of patients with human immunodeficiency virus (HIV) infection (1–4). The course of chronic HCV is accelerated in
HIV/HCV-coinfected patients, with more rapid progression of liver fibrosis compared to HCV-monoinfected patients (5–7). Consequently, HCV-related liver complications, particularly hepatic decompensation (defined by the presence of ascites, spontaneous bacterial peritonitis, variceal hemorrhage, or hepatic encephalopathy (8)), have emerged as important causes of morbidity in coinfected patients (9, 10).

Despite the importance of HCV-related end-stage liver disease, few longitudinal studies have evaluated the incidence and determinants of hepatic decompensation among HIV/HCV-coinfected persons during the antiretroviral therapy (ART) era. Previous studies suggest that ART slows progression of HCV-associated liver fibrosis, possibly by reducing HIV-related inflammation and immune dysfunction and inhibiting the ability of HIV to directly infect hepatocytes (10–13). However, it remains unclear if rates of hepatic decompensation and other severe liver events (e.g., hepatocellular carcinoma [HCC], liver-related death) in coinfected patients on ART are similar to those of HCV-monoinfected patients. Further, the determinants of hepatic decompensation among coinfected patients on ART remain unknown. Determination of these factors could help define the mechanisms of decompensation in coinfected patients and suggest interventions to reduce the risk of end-stage liver disease in this population.

We first compared the incidence of hepatic decompensation between antiretroviral-treated HIV/HCV-coinfected and HCV-monoinfected patients. We hypothesized that rates of decompensation would remain higher in coinfected patients despite ART. We then evaluated host and viral factors associated with decompensation among coinfected patients.

**METHODS**

**Study Design and Data Source**

We conducted a retrospective cohort study among antiretroviral-treated HIV/HCV-coinfected and HCV-monoinfected patients in the Veterans Aging Cohort Study Virtual Cohort (VACS-VC) between January 1, 1997 and September 30, 2010 (14). The VACS-VC consists of electronic medical record data from HIV-infected patients receiving care at Veterans Affairs (VA) medical facilities across the US. Each HIV-infected patient is matched on age, sex, race/ethnicity, and site to two HIV-uninfected patients. Data include hospital and outpatient diagnoses (recorded using International Classification of Diseases, Ninth Revision [ICD-9] codes), procedures (recorded using Current Procedural Terminology [CPT] codes), laboratory results, and pharmacy data. Clinically confirmed cancer diagnoses are available from the VA Central Cancer Registry. Deaths are identified from the VA Vital Status file, which determines mortality using the Social Security Death Master File, Medicare Vital Status Files, and VA Beneficiary Identification and Records Locator Subsystem. For patients who died, principal cause of death can be determined by linkage with the National Death Index (15). Additionally, U.S. Medicare and Medicaid claims data are available for veterans also enrolled in these programs and have been merged with VACS-VC data.
**Study Patients**

Coinfected patients were included if they had: 1) detectable HCV RNA, 2) newly initiated ART (defined as use of at least three antiretrovirals from two different classes (16) or ≥3 nucleoside analogues [a previously accepted ART regimen (17)] within the VA system, 3) HIV RNA >500 copies/mL within 180 days prior to initiating ART (to identify new ART initiators (18)), and 4) at least 12 months of observation in the VACS-VC after starting ART. Monoinfected patients had: 1) detectable HCV RNA, 2) no recorded HIV ICD-9 diagnosis or antiretroviral prescriptions, and 3) at least 12 months of observation in the VACS-VC. Patients were excluded if during the baseline period (defined below) they had: 1) hepatic decompensation, 2) HCC, 3) liver transplantation, or 4) received interferon-based HCV therapy (since treatment reduces the risk of hepatic decompensation (19, 20)).

**Main Study Outcomes**

The primary outcome was incident hepatic decompensation, which was defined by one hospital discharge ICD-9 diagnosis or two or more outpatient ICD-9 diagnoses of ascites, spontaneous bacterial peritonitis, or esophageal variceal hemorrhage in the VACS-VC (Appendix A). A prior study validated this determination, with 91% of events confirmed by medical records (21). The requirement of two outpatient diagnoses aimed to exclude events that were suspected but not subsequently confirmed at follow-up visits. Based on the results of the prior validation study (21), we did not include ICD-9 diagnoses for hepatic encephalopathy and jaundice, which could indicate decompensation, because these diagnoses frequently were linked to unrelated conditions (e.g., narcotic overuse, stroke recorded as encephalopathy; biliary obstruction, atazanavir-associated hyperbilirubinemia recorded as jaundice). Date of decompensation was defined as the hospital discharge date (if identified by hospital diagnosis) or initial outpatient diagnosis date (if identified by outpatient diagnoses).

Secondary outcomes included: 1) incident hepatic decompensation (determined by the above ICD-9-based definition) within VACS-VC, Medicare, or Medicaid data (to capture outcomes occurring at non-VA hospitals that did not result in transfer to a VA facility; this outcome was secondary because non-VA events have not been validated), 2) HCC, and 3) severe liver events, a composite outcome of hepatic decompensation within the VACS-VC, HCC, or liver-related death. HCC was determined using the VA Central Cancer Registry, which confirmed diagnoses by histology, cytology, or consistent radiography. Deaths were classified as liver-related if the underlying cause of death from the National Death Index was recorded as hepatic decompensation, liver cancer, alcoholic liver disease, viral hepatitis, or non-alcoholic liver disease (Appendix A) (15).

**Data Collection**

Baseline data (Table 1) included: age; sex; race/ethnicity; VA center patient volume; body mass index (BMI); diabetes mellitus; alcohol dependence/abuse; injection/non-injection drug use; hepatitis B surface antigen status; HCV genotype; HCV RNA; pre-ART CD4 count; pre-ART plasma HIV RNA; and baseline antiretroviral regimen. Diabetes was defined by random glucose level ≥200 mg/dL or anti-diabetic medication use (22, 23). Alcohol dependence/abuse (24) and injection/non-injection drug use (24, 25) were defined...
by previously validated ICD-9 diagnoses (Appendix A). Baseline serum creatinine, hemoglobin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and platelet count were collected from dates closest to but prior to start of follow-up. Baseline FIB-4, a noninvasive measure of advanced hepatic fibrosis, was determined by: (age [years] × AST [U/L])/((platelet count [10^9/L]) × (ALT [U/L])^1/2) (26). Because liver fibrosis can progress by one stage as early as within 4 years for antiretroviral-treated HIV/HCV-coinfected persons (7) and within 5 years for HCV-monoinfected persons (27), we determined baseline FIB-4 scores using ALT, AST, and platelet counts within a 2-year period around the start of follow-up. FIB-4 scores <1.45 identify no/minimal fibrosis and scores >3.25 indicate advanced hepatic fibrosis/cirrhosis in coinfected (26) and HCV-monoinfected patients (28).

Longitudinal data included hepatitis B surface antigen, plasma HIV RNA, diabetes, and liver transplantation (determined by diagnosis and procedural codes; Appendix A).

**Statistical Analysis**

The 12 months prior to the start of follow-up represented the baseline period for both cohorts. Follow-up for coinfected patients began 12 months after ART initiation and for monoinfected patients after 12 months in the VACS-VC. The rationale for defining the baseline period as the first year on ART for coinfected patients was due to the fact that many of these patients initially entered into care at the time of ART initiation, which was shortly after their HIV diagnosis. Follow-up continued until a study endpoint, death, initiation of HCV therapy, or last visit before September 30, 2010.

For descriptive purposes, we estimated incidence rates (events/1,000 person-years) of endpoints with 95% confidence intervals (CIs), standardized by the age and race/ethnicity distribution of coinfected patients (29). We then used Cox models to estimate adjusted hazard ratios (HRs) of outcomes in coinfected compared to monoinfected patients (30). We controlled for all available clinically relevant variables in Table 1. The proportionality of hazards was evaluated by plots of Schoenfeld residuals (31). As a sensitivity analysis, we addressed the potential for informative censoring by use of inverse probability of censoring weights and Cox regression (Appendix B) (32).

Since mortality rates were higher for coinfected than monoinfected patients and because death could be a competing risk for decompensation, we determined HRs of decompensation accounting for death as a competing risk (33). We estimated the incidence of decompensation for both cohorts, standardized to the characteristics of patients in the overall sample based on the covariates in the Cox model (Table 2) and assuming that death was a competing risk.

We also performed three subgroup analyses. First, since coinfected patients may have had varying antiretroviral adherence during follow-up or might have interrupted or discontinued ART leading to virologic failure, we compared decompensation rates in the monoinfected cohort to subgroups of coinfected patients stratified by HIV RNA level during follow-up (<1,000 copies/mL on all HIV RNA results during follow-up; ≥1,000 copies/mL on any result during follow-up). This threshold was chosen because intermittent low-level HIV viremia <1,000 copies/mL may occur among patients on ART and is not necessarily
indicative of HIV virologic failure (34). As a sensitivity analysis, we compared
decompensation rates in the much smaller subgroup of coinfected patients who maintained
HIV RNA <400 copies/mL throughout follow-up (n=386) compared to monoinfected
patients. Second, we compared decompensation rates in the monoinfected cohort to
coinfected patients stratified by pre-ART CD4 count (<200; 200–349; 350–499; ≥500
cells/mm$^3$). Third, we evaluated the risk of decompensation between coinfected and
monoinfected patients at the same baseline stage of liver fibrosis. This analysis focused on
patients with no/minimal hepatic fibrosis (determined by FIB-4 <1.45) to be able to fully
evaluate the association between coinfection and decompensation.

Among coinfected patients, we used Cox and competing risk regression analyses to estimate
HRs of decompensation for risk factors of interest. Hypothesized risk factors included:
baseline advanced hepatic fibrosis (FIB-4 >3.25), baseline obesity (BMI ≥30 kg/m$^2$),
baseline severe anemia (hemoglobin <10 g/dL), diabetes mellitus, active hepatitis B
infection, non-black race, pre-ART CD4 count, and HIV viremia copy-years, defined as the
log copies of plasma HIV RNA/mL over time, which is a measure of cumulative plasma
HIV burden (35). Viremia copy-years were estimated by the cumulative annual HIV viral
load based on the median value of each year of follow-up. Details are presented in Appendix
C. Diabetes, hepatitis B, and HIV viremia copy-years were evaluated as time-varying
covariates.

In a subgroup analysis among 3,314 (77.4%) coinfected patients with baseline HCV RNA
results reported in international units (IU)/mL, we evaluated the association between high
baseline HCV RNA level (≥400,000 IU/mL) and decompensation. If multiple baseline HCV
RNA loads were available, the highest result was analyzed.

We performed a simulation-based sensitivity analysis to examine the effect of unmeasured
confounders on the HR of decompensation between coinfected and monoinfected patients
(36). Details appear in Appendix D.

We implemented multiple imputation to address the potential bias of missing data, by means
of 10 imputations using all variables in Table 1 and outcomes (37). Results across the 10
datasets were combined to arrive at CIs that accounted for within- and across-dataset
variances (38). Data were analyzed using SAS 9.2 (SAS Institute Inc., Cary, NC) and Stata
12.1 (Stata Corporation, College Station, TX).

**Regulatory Approvals**

This study was approved by the Institutional Review Boards of the University of
Pennsylvania and Philadelphia VA Medical Center.

**Role of the Funding Sources**

The study was funded by the National Institutes of Health. The funding source had no role in
data collection, analysis, or interpretation.
RESULTS

Patient characteristics

Between 1997 and 2010, 10,359 patients (4,280 antiretroviral-treated HIV/HCV-coinfected; 6,079 HCV-monoinfected) met our inclusion criteria (Figure 1). Absence of HCV RNA assessment was the most common reason for exclusion from both cohorts. There were no clinically relevant differences in the characteristics between included patients (Table 1) and those excluded due to lack of HCV RNA for both cohorts.

Table 1 summarizes the baseline cohort characteristics. Coinfected and monoinfected patients were similar in age, race/ethnicity, diabetes, history of alcohol dependence/abuse, and history of injection/non-injection drug use. The majority of both cohorts were infected with HCV genotype 1. Coinfected patients more commonly had a high HCV RNA level. Follow-up was shorter for coinfected than monoinfected patients (6.8 versus 9.9 years; p<0.001). During follow-up, 330 (7.7%) coinfected and 505 (8.3%) monoinfected patients initiated HCV therapy and were censored.

Baseline ART regimens prescribed to HIV/HCV-coinfected patients reflected the antiretroviral drugs used at the time of VACS-VC entry (Table 1). Only very few (162 [3.8%]) were prescribed abacavir/lamivudine/zidovudine as their baseline regimen. Among the 241 hepatitis B surface antigen-positive HIV/HCV-coinfected patients, 207 (85.9%) received lamivudine alone, tenofovir plus emtricitabine, or tenofovir plus lamivudine as part of their baseline regimen. HIV/HCV-coinfected patients had a median of 2.8 (interquartile range, 1.8–3.8) HIV RNA results measured each year during follow-up to assess HIV virologic response.

Hepatic decompensation

Hepatic decompensation occurred more frequently in antiretroviral-treated coinfected than monoinfected patients (271 [6.3%] versus 305 [5.0%]; p=0.004). At the time of initial decompensation, variceal hemorrhage was less common among coinfected patients (71 [26.2%] versus 168 [55.1%]; p<0.001). However, similar proportions of coinfected and monoinfected patients presented with ascites (226 [83.4%] versus 236 [77.4%]; p=0.070) and spontaneous bacterial peritonitis (48 [17.7%] versus 68 [22.3%]; p=0.171). Among those who presented with ascites, similar proportions of coinfected and monoinfected patients had the diagnosis recorded in the inpatient setting (145 [64.2%] versus 133 [56.4%]; p=0.087).

After adjustment for age, race/ethnicity, diabetes, BMI, history of alcohol abuse and injection/non-injection drug use, and VA center volume, coinfected patients on ART had a higher rate of decompensation than monoinfected patients (HR, 1.83 [95% CI, 1.54–2.18]). This association was almost identical when we expanded our outcome to include VA, Medicare, or Medicaid events (HR, 1.85 [95% CI, 1.59–2.18]) and remained when death was treated as a competing risk (HR, 1.56 [95% CI, 1.31–1.86]). HRs adjusted for informative censoring differed little (data not shown). The standardized cumulative incidence of decompensation was higher among coinfected than monoinfected patients at 10 years (7.4% versus 4.8%; p<0.001; Figure 2a).
In subgroup analyses, rates of decompensation remained higher in coinfected patients who maintained HIV RNA levels <1,000 copies/mL throughout follow-up compared to monoinfected persons (Table 2; Figure 2b). Similar results were observed when coinfected patients with HIV RNA <400 copies/mL throughout follow-up were compared to HCV-monoinfected patients (data not shown). Across strata of pre-ART CD4 count, the hazard ratio of decompensation was highest for coinfected patients with a pre-ART CD4 count of <200 cells/mm$^3$ compared to monoinfected persons (Table 2; Figure 2c). Among those with a baseline FIB-4 <1.45, the risk of decompensation remained higher in coinfected than monoinfected patients (adjusted HR, 1.98 [95% CI, 1.23–3.18]).

**Hepatocellular carcinoma**

The proportion of coinfected and monoinfected patients who developed HCC was similar between the cohorts (74 [1.7%] versus 100 [1.6%]; p=0.74). After adjustment for age, race, diabetes, BMI, alcohol abuse, injection/non-injection drug use, and center volume, rates of HCC were higher for coinfected patients (HR, 1.60 [95% CI, 1.16–2.21]). This association did not remain significant in competing risk analysis (Table 2). Median survival after HCC diagnosis was shorter for coinfected patients (8.7 [IQR, 2.3–27.3] versus 14.2 [IQR, 3.8–101.8] months), but this difference was not significant (p=0.22). There were no important differences in age at diagnosis, race, BMI, diabetes, or alcohol abuse between coinfected and monoinfected patients with HCC (Appendix E).

**Severe liver events and death**

Severe liver events were more common in coinfected than monoinfected patients (373 [8.7%] versus 433 [7.1%]; p=0.003). Further, coinfected patients had a higher risk of this endpoint (Table 2). Coinfected patients less commonly underwent liver transplantation (5 [0.1%] vs. 26 [0.4%]; p=0.004).

Mortality occurred more frequently among coinfected patients (1,407 [32.9%] vs. 934 [15.4%]; p<0.001). HIV/AIDS was most commonly recorded as the underlying cause of death in this cohort (46.3%). Liver disease was the most common cause of death in monoinfected patients (20.1%; Appendix F).

**Factors associated with decompensation among coinfected patients**

Baseline advanced hepatic fibrosis, baseline hemoglobin <10 g/dL, diabetes, and non-black race were risk factors for decompensation (Table 3). The hazard for HIV viremia copy-years >6 log copy-years/mL was approximately twice that of the reference group (<2 log copy-years/mL), but these results did not approach statistical significance.

The incidence of decompensation was similar between coinfected patients with baseline HCV RNA ≥400,000 IU/mL compared to <400,000 IU/mL (5.8% [169/2,936] versus 6.9% [26/378]; HR, 0.78 [95% CI, 0.52–1.18]). Results were similar for competing risk regression analyses (data not shown).
DISCUSSION

In this study, antiretroviral-treated HIV/HCV-coinfected patients had higher rates of hepatic decompensation and severe liver events compared to HCV-monoinfected patients. Coinfected patients who maintained HIV RNA levels <1,000 copies/mL or <400 copies/mL over the median 6.8 years of follow-up still had higher rates of decompensation, suggesting that HIV viral suppression below these thresholds with ART is not sufficient to reduce rates of end-stage liver disease to those of HCV-monoinfected patients. Further, among patients with minimal/no fibrosis at baseline, the risk of decompensation remained higher for coinfected patients. Rates of decompensation were highest for patients with pre-ART CD4 counts <200 cells/mm$^3$ compared to monoinfected patients. Finally, among coinfected patients on ART, baseline advanced liver fibrosis, severe anemia, diabetes, and non-black race were each associated with higher rates of decompensation.

Our analyses examining the risk of decompensation between coinfected and monoinfected patients did not control for baseline stage of hepatic fibrosis because the development of liver fibrosis is in the causal pathway to hepatic decompensation. Thus, controlling for baseline hepatic fibrosis could potentially adjust away an association between treated HIV and decompensated cirrhosis. Therefore, we conducted a secondary analysis restricted to patients with minimal/no liver fibrosis (FIB-4 <1.45) at baseline. Antiretroviral-treated coinfected patients continued to have an increased risk of hepatic decompensation compared to monoinfected patients.

The mechanisms for the higher rates of hepatic decompensation in coinfected patients on ART remain unclear. HIV-related immune dysregulation, HIV-mediated depletion of CD4 cells in the gastrointestinal tract with resultant microbial translocation, HIV/HCV-related oxidative stress, and HIV-induced hepatocyte apoptosis have been implicated in the pathogenesis of progressive hepatic disease in HIV/HCV-coinfected patients (13). Other cofactors, such as hepatic steatosis and cumulative exposure to potentially hepatotoxic medications, particularly select antiretroviral drugs (39–41), might also accelerate liver disease progression in coinfected patients.

We observed that variceal hemorrhage was less commonly an initial presenting decompensation event among coinfected patients. A similar finding was reported in a cohort study of HIV/HCV-coinfected patients from Spain (42). Prior studies have suggested that HIV infection is associated with protein C deficiency (43–45) and protein S deficiency (46), which can promote hypercoagulability and reduce the likelihood of variceal bleeding among coinfected patients.

We observed a higher rate of HCC in coinfected patients on ART compared to HCV-monoinfected patients, but this difference was not statistically significant after adjustment for competing risk. A prior cohort study conducted between 1992 and 2000 showed that HIV/HCV coinfection was not associated with an increased risk of HCC either in the pre-ART or ART eras compared to HCV-monoinfection (47). As life expectancy continues to extend among HIV/HCV-coinfected patients, clinically important differences in rates of HCC may become apparent in the future.
We identified several important factors associated with hepatic decompensation in coinfected patients. Diabetes is associated with hepatic steatosis (48), which could promote hepatic inflammation and accelerate liver fibrosis progression (49). Diabetes might also induce hepatic fibrosis independent of steatosis via stimulation of hepatic stellate cells by insulin (50, 51). Severe anemia might be a marker of advanced HCV-associated liver disease, potentially indicating blood loss from variceal bleeding. Alternatively, anemia may be a marker for systemic inflammation (52), which may promote hepatic fibrosis. Non-black HCV-infected patients are reported to have stronger HCV-specific immunity than those of black race (53), which could result in increased immune-mediated hepatic inflammation and accelerated liver fibrosis progression.

Our results suggest that the highest level of HIV viremia copy-years (>6 log copy-years/mL of HIV RNA) might increase the risk of hepatic decompensation. However, plasma viral loads were measured infrequently in many patients, with variable numbers and timing. Given our additional finding of a higher risk of decompensation for coinfected patients with pre-ART CD4 counts <200 cell/mm$^3$ compared to monoinfected persons, suppression of HIV on ART with resultant immune reconstitution should remain a key goal for HIV/HCV patients to possibly reduce the risk of end-stage liver disease.

Neither hepatitis B infection nor HCV RNA level was associated with hepatic decompensation among coinfected patients. The majority (85.9%) of coinfected patients who were hepatitis B surface antigen-positive received hepatitis B-active ART, and this might have mitigated the association between hepatitis B and decompensation. Future analyses should test this hypothesis. Moreover, while several studies in HCV-monoinfected patients have suggested that higher HCV RNA levels are associated with more advanced liver fibrosis (54–56) or death from end-stage liver disease (57), the majority have found no association between HCV RNA level and liver disease severity (58–62). Our results are consistent with these findings.

Our results have important clinical implications. The finding that antiretroviral-treated coinfected patients who maintained an HIV RNA <1,000 copies/mL had lower rates of hepatic decompensation compared to those who did not achieve HIV suppression below this level suggests that suppression of HIV RNA with ART is an important factor in slowing progression of HCV-related liver fibrosis. This observation supports current management guidelines that recommend initiation of ART among HIV/HCV-coinfected patients, regardless of CD4 cell count (16, 63). Further, the increased rate of hepatic decompensation among coinfected patients should prompt earlier consideration for initiating HCV therapy to try to reduce the risk of liver complications (19, 20). Recent clinical trials evaluating boceprevir- and telaprevir-based antiviral therapy among HIV/HCV genotype 1-coinfected patients demonstrate sustained HCV virologic response rates that are comparable to those of HCV-monoinfected patients (64, 65). Providers might also address modifiable risk factors (e.g., control diabetes) to try to decrease the risk of end-stage liver disease.

This study has several potential limitations. Decompensation outcomes could have been misclassified. However, hepatic decompensation was identified using a validated definition (21). We might have underestimated the number of decompensation events since our
definition did not include hepatic encephalopathy. However, the negative predictive value of our validated definition exceeded 99% (21). Further, the incidence rates of decompensation among coinfected (9.5/1,000 person-years) and monoinfected (5.7/1,000 person-years) patients in this study were similar to those reported in other cohorts of coinfected (11.6/1,000 person-years (10)) and monoinfected (3.4/1,000 person-years (62)) patients. There is the potential for differential ascertainment of outcomes if patients in one of the cohorts more frequently presented to non-VA hospitals for care. To address this issue, we evaluated: 1) incident decompensation events within the VA system as well as in the U.S. Medicare and Medicaid programs, and 2) liver-related deaths within a composite severe liver event outcome. The association between antiretroviral-treated coinfection and these composite endpoints remained in both analyses. Second, residual confounding by unmeasured factors (e.g., duration of HCV infection; alcohol dependence/drug use during follow-up) is possible. However, sensitivity analyses (Appendix D) suggested that our results were robust to the potential bias from unobserved confounders. Third, the median follow-up among the monoinfected cohort was longer than that for the coinfected cohort. However, both cohorts included patients in all age groups, produced risk sets of adequate size for all combinations of decompensation risk factors across age groups, and therefore covered the spectrum of risks experienced by young, middle-aged, and older HCV-infected patients. Finally, our study sample was predominantly comprised of male U.S. veterans, and so results may not be generalizable to women. Since HCV-related liver fibrosis progression differs by sex (60, 66, 67), future epidemiologic analyses should evaluate end-stage liver disease events among HIV/HCV-coinfected and HCV-monoinfected women.

This study had a number of strengths. It is the largest study evaluating liver-related events among antiretroviral-treated coinfection patients and compared outcomes to HCV-monoinfected persons. It had a long duration of follow-up, evaluated validated endpoints (21), accounted for time-varying covariates, and identified decompensations and liver-related deaths outside the VA system, ensuring that few outcomes were missed.

In conclusion, we observed that HIV/HCV-coinfected patients receiving ART had higher rates of hepatic decompensation and severe liver events than HCV-monoinfected individuals. Among coinfected patients on ART, baseline advanced liver fibrosis, severe anemia, diabetes, and non-black race were associated with higher rates of decompensation. Clinicians should address modifiable risk factors and consider treatment of HCV infection in coinfected patients to reduce rates of hepatic decompensation.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgments**

We are grateful to the VA Central Cancer Registry for permitting us to link the VACS Virtual Cohort database with the VA Central Cancer Registry database and for providing us with a dataset containing the linked records.

**Grant Support:** National Institute of Allergy and Infectious Diseases research grant K01 AI070001 [Dr. Lo Re], National Institute on Alcohol Abuse and Alcoholism research grant U01 AA13566 [Dr. Justice], and National Institute of Mental Health research grant T32 MH020031 [Ms. Park].
Abbreviations

ART  antiretroviral therapy
HCC  hepatocellular carcinoma
HCV  hepatitis C virus
HIV  human immunodeficiency virus infection
VA  Veterans Affairs

References


Ann Intern Med. Author manuscript; available in PMC 2014 December 04.


HIV/Hepatitis C Virus-Coinfected

44,180
HIV-Infected Patients in the VACS Virtual Cohort (1997-2010)

14,832
HIV/HCV Antibody-Positive Patients in the VACS Virtual Cohort (1997-2010)

9,614
HIV/HCV Antibody-Positive Patients on Antiretroviral Therapy in the VACS Virtual Cohort (1997-2010)

5,334 Excluded:
- 528 Without at least 12 months of follow-up
- 122 Had hepatic decompensation, hepatocellular carcinoma, or liver transplant prior to follow-up
- 62 Received interferon-based therapy prior to follow-up
- 1,466 Had an HIV RNA <500 copies/mL within 180 days prior to initiation of antiretroviral therapy
- 1,089 Missing HIV RNA within 180 days prior to initiation of antiretroviral therapy
- 851 Had a negative HCV RNA level
- 1,216 Missing HCV RNA level

4,280
Antiretroviral-Treated HIV/HCV Patients Included in the Study
Figure 1.
Selection of antiretroviral-treated HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients for inclusion in the study.
* HIV infection determined by International Classification of Diseases, Ninth Revision diagnosis codes.
Figure 2.
Standardized cumulative incidences of hepatic decompensation, based on competing risk regression analyses. Estimates of the cumulative incidence of hepatic decompensation are reported for each group.

a. Standardized cumulative incidences of hepatic decompensation between antiretroviral-treated HIV/hepatitis C virus-coinfected (denoted by solid line) and hepatitis C virus-monoinfected patients (denoted by dotted line).

b. Standardized cumulative incidences of hepatic decompensation between antiretroviral-treated HIV/hepatitis C virus-coinfected patients with HIV RNA levels ≥1,000 copies/mL on any HIV RNA test result during follow-up (denoted by dashed line), antiretroviral-treated HIV/hepatitis C virus-coinfected patients with HIV RNA <1,000 copies/mL on all HIV RNA test results throughout follow-up (denoted by solid line), and hepatitis C virus-monoinfected patients (denoted by dotted line).

c. Standardized cumulative incidences of hepatic decompensation between antiretroviral-treated HIV/hepatitis C virus-coinfected patients with pre-antiretroviral therapy CD4 T lymphocyte counts <200 cells/mm$^3$ (denoted by solid line), antiretroviral-treated HIV/hepatitis C virus-coinfected patients with pre-antiretroviral therapy CD4 T lymphocyte counts ≥200 cells/mm$^3$ (denoted by dashed line), and hepatitis C virus-monoinfected patients (denoted by dotted line). Strata for CD4 cell counts ≥200 cells/mm$^3$ were collapsed into a single plot because these HRs were indistinguishable (see Table 2).
Table 1
Characteristics of the study cohorts.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Antiretroviral-Treated HIV/HCV-Coinfected (n=4,280)</th>
<th>HCV-Monoinfected (n=6,079)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median baseline age (years, IQR)</td>
<td>48 (44–52)</td>
<td>47 (43–50)</td>
</tr>
<tr>
<td>Male sex (n, %)</td>
<td>4,214 (98.5)</td>
<td>6,022 (99.1)</td>
</tr>
<tr>
<td>Race/ethnicity (n, %)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>2,788 (65.1)</td>
<td>3,733 (61.4)</td>
</tr>
<tr>
<td>Caucasian</td>
<td>975 (22.8)</td>
<td>1,775 (29.2)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>414 (9.7)</td>
<td>477 (7.8)</td>
</tr>
<tr>
<td>Other/Unknown</td>
<td>103 (2.4)</td>
<td>94 (1.5)</td>
</tr>
<tr>
<td>Baseline body mass index (n, %)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;18.5 kg/m²</td>
<td>135 (3.2)</td>
<td>107 (1.8)</td>
</tr>
<tr>
<td>18.5–24.9 kg/m²</td>
<td>2,184 (51.0)</td>
<td>2,006 (33.0)</td>
</tr>
<tr>
<td>25–29.9 kg/m²</td>
<td>1,368 (32.0)</td>
<td>2,242 (36.9)</td>
</tr>
<tr>
<td>≥30 kg/m²</td>
<td>473 (11.1)</td>
<td>1,669 (27.5)</td>
</tr>
<tr>
<td>Missing weight and/or height</td>
<td>120 (2.8)</td>
<td>55 (0.9)</td>
</tr>
<tr>
<td>Baseline diabetes mellitus (n, %)</td>
<td>318 (7.4)</td>
<td>453 (7.5)</td>
</tr>
<tr>
<td>Baseline history of alcohol dependence/abuse (n, %)</td>
<td>1,130 (26.4)</td>
<td>1,866 (30.7)</td>
</tr>
<tr>
<td>Baseline history of injection/non-injection drug use (n, %)</td>
<td>1,501 (35.1)</td>
<td>2,025 (33.3)</td>
</tr>
<tr>
<td>Baseline history of tobacco use (n, %)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>2,956 (69.1)</td>
<td>4,457 (73.3)</td>
</tr>
<tr>
<td>Former</td>
<td>482 (11.3)</td>
<td>776 (12.8)</td>
</tr>
<tr>
<td>Never</td>
<td>486 (11.4)</td>
<td>650 (10.7)</td>
</tr>
<tr>
<td>Unknown</td>
<td>356 (8.2)</td>
<td>196 (3.2)</td>
</tr>
<tr>
<td>Median follow-up (years, IQR)</td>
<td>6.8 (3.6–10.1)</td>
<td>9.9 (6.0–12.4)</td>
</tr>
<tr>
<td>Total follow-up time (person-years)</td>
<td>29,005</td>
<td>54,411</td>
</tr>
<tr>
<td>HCV genotype (n, %)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 or 4</td>
<td>2,513 (58.7)</td>
<td>3,648 (60.0)</td>
</tr>
<tr>
<td>2 or 3</td>
<td>315 (7.4)</td>
<td>513 (8.4)</td>
</tr>
<tr>
<td>Other</td>
<td>7 (0.2)</td>
<td>11 (0.2)</td>
</tr>
<tr>
<td>Missing</td>
<td>1,445 (33.8)</td>
<td>1,907 (31.4)</td>
</tr>
<tr>
<td>Baseline HCV RNA (n, %)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥400,000 IU/mL and/or ≥1,000,000 copies/mL</td>
<td>3,186 (74.5)</td>
<td>2,309 (38.0)</td>
</tr>
<tr>
<td>&lt;400,000 IU/mL and/or &lt;1,000,000 copies/mL</td>
<td>450 (10.5)</td>
<td>2,006 (33.0)</td>
</tr>
<tr>
<td>Qualitative HCV RNA result only</td>
<td>644 (15.0)</td>
<td>1,764 (29.0)</td>
</tr>
<tr>
<td>Hepatitis B surface antigen (n, %)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive (ever)</td>
<td>241 (5.6)</td>
<td>78 (1.3)</td>
</tr>
<tr>
<td>Negative</td>
<td>3,992 (93.3)</td>
<td>5,701 (93.8)</td>
</tr>
<tr>
<td>Never tested</td>
<td>47 (1.1)</td>
<td>300 (4.9)</td>
</tr>
<tr>
<td>Median pre-ART HIV RNA (log copies/mL, IQR)</td>
<td>4.7 (4.0–5.1)</td>
<td>–</td>
</tr>
<tr>
<td>Pre-ART CD4 cell count (n, %)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Characteristic</td>
<td>Antiretroviral-Treated HIV/HCV-Coinfected (n=4,280)</td>
<td>HCV-Monoinfected (n=6,079)</td>
</tr>
<tr>
<td>----------------------</td>
<td>---------------------------------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>≥500 cells/mm³</td>
<td>391 (9.1)</td>
<td>-</td>
</tr>
<tr>
<td>350–499 cells/mm³</td>
<td>588 (13.7)</td>
<td>-</td>
</tr>
<tr>
<td>200–349 cells/mm³</td>
<td>1,279 (29.9)</td>
<td>-</td>
</tr>
<tr>
<td>&lt;200 cells/mm³</td>
<td>1,921 (44.9)</td>
<td>-</td>
</tr>
<tr>
<td>Not tested at baseline</td>
<td>101 (2.4)</td>
<td>-</td>
</tr>
</tbody>
</table>

**Most common baseline antiretroviral regimens (n, %)**

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Antiretroviral-Treated HIV/HCV-Coinfected</th>
<th>HCV-Monoinfected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nelfinavir/zidovudine/lamivudine</td>
<td>553 (12.9)</td>
<td>-</td>
</tr>
<tr>
<td>Efavirenz/zidovudine/lamivudine</td>
<td>551 (12.9)</td>
<td>-</td>
</tr>
<tr>
<td>Indinavir/zidovudine/lamivudine</td>
<td>545 (12.7)</td>
<td>-</td>
</tr>
<tr>
<td>Indinavir/stavudine/lamivudine</td>
<td>391 (9.1)</td>
<td>-</td>
</tr>
<tr>
<td>Efavirenz/tenofovir/lamivudine</td>
<td>268 (6.3)</td>
<td>-</td>
</tr>
<tr>
<td>Nevirapine/zidovudine/lamivudine</td>
<td>237 (5.5)</td>
<td>-</td>
</tr>
</tbody>
</table>

Abbreviations: HCV=hepatitis C virus; HIV=human immunodeficiency virus; IQR=interquartile range; RNA=ribonucleic acid

* Based on highest baseline HCV RNA result
### Table 2
Incidence rates, standardized for age and race/ethnicity, and adjusted relative hazards of specified liver-related outcomes in antiretroviral-treated HIV/hepatitis C-coinfected compared to hepatitis C-monoinfected patients.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Incidence Rate (95% Confidence Interval [CI]), Events/1,000 Person-Years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Antiretroviral-Treated HIV/HCV-Coinfected (n=4,280)</td>
</tr>
<tr>
<td></td>
<td>Adjusted HR with 95% CI&lt;sup&gt;*&lt;/sup&gt; (Death is Censored)</td>
</tr>
<tr>
<td>Hepatic decompensation</td>
<td></td>
</tr>
<tr>
<td>All patients (n=10,359)</td>
<td>9.5 (7.6–11.9)</td>
</tr>
<tr>
<td>HIV/HCV patients with:</td>
<td></td>
</tr>
<tr>
<td>HIV RNA &lt;1,000 copies/mL during follow-up (n=966&lt;sup&gt;†&lt;/sup&gt;)</td>
<td>9.4 (5.4–16.2)</td>
</tr>
<tr>
<td>HIV RNA ≥1,000 copies/mL during follow-up (n=3,180&lt;sup&gt;†&lt;/sup&gt;)</td>
<td>9.6 (7.5–12.2)</td>
</tr>
<tr>
<td>Pre-ART CD4 cell count ≥500 cells/mm&lt;sup&gt;3&lt;/sup&gt; (n=391&lt;sup&gt;†&lt;/sup&gt;)</td>
<td>8.8 (4.4–17.8)</td>
</tr>
<tr>
<td>Pre-ART CD4 cell count 350–499 cells/mm&lt;sup&gt;3&lt;/sup&gt; (n=588&lt;sup&gt;‡&lt;/sup&gt;)</td>
<td>8.1 (4.4–14.8)</td>
</tr>
<tr>
<td>Pre-ART CD4 cell count 200–349 cells/mm&lt;sup&gt;3&lt;/sup&gt; (n=1,279&lt;sup&gt;‡&lt;/sup&gt;)</td>
<td>8.6 (5.6–13.1)</td>
</tr>
<tr>
<td>Pre-ART CD4 cell count &lt;200 cells/mm&lt;sup&gt;3&lt;/sup&gt; (n=1,921&lt;sup&gt;‡&lt;/sup&gt;)</td>
<td>10.9 (7.9–15.0)</td>
</tr>
<tr>
<td>Hepatocellular carcinoma (n=10,359)</td>
<td>2.4 (1.7–3.4)</td>
</tr>
<tr>
<td>Severe liver events (n=10,359)</td>
<td>12.9 (10.8–15.5)</td>
</tr>
</tbody>
</table>

Abbreviations: ART=antiretroviral therapy; CI=confidence interval; HIV=human immunodeficiency virus; HR=hazard ratio

<sup>*</sup> Hazard ratios adjusted for age, race, diabetes mellitus, body mass index, history of alcohol dependence/abuse, history of injection/non-injection drug use, and VA center patient volume. The proportion of hepatitis C-monoinfected patients who had a hemoglobin and hepatitis B surface antigen result determined during the baseline period was very small. As a result, these variables were not included in multivariable models comparing incidence rates of hepatic decompensation between antiretroviral-treated HIV/HCV-coinfected and HCV-monoinfected patients.

<sup>‡</sup> Because the HRs for strata ≥200 cells/mm<sup>3</sup> were indistinguishable, they are displayed as a single plot in Figure 2c.

Re et al. Page 22
# Table 3
Factors associated with hepatic decompensation among 4,280 antiretroviral-treated HIV/hepatitis C virus-coinfected patients.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Adjusted HR with 95% CI*</th>
<th>Adjusted HR with 95% CI†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(Death is Censored)</td>
<td>(Death is a Competing Risk)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;18.5</td>
<td>0.58 (0.22–1.52)</td>
<td>0.46 (0.17–1.23)</td>
</tr>
<tr>
<td>18.5–24.9</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>25–29.9</td>
<td>1.09 (0.83–1.42)</td>
<td>1.13 (0.86–1.47)</td>
</tr>
<tr>
<td>≥30</td>
<td>1.04 (0.69–1.56)</td>
<td>1.07 (0.71–1.62)</td>
</tr>
<tr>
<td>Diabetes mellitus†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>Present</td>
<td>1.88 (1.39–2.53)</td>
<td>1.88 (1.38–2.56)</td>
</tr>
<tr>
<td>FIB-4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1.45</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>1.45–3.25</td>
<td>1.99 (1.39–2.85)</td>
<td>1.91 (1.33–2.73)</td>
</tr>
<tr>
<td>&gt;3.25</td>
<td>6.54 (4.56–9.39)</td>
<td>5.45 (3.79–7.84)</td>
</tr>
<tr>
<td>Hemoglobin (g/dL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥10</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>&lt;10</td>
<td>3.50 (1.97–6.24)</td>
<td>2.24 (1.20–4.20)</td>
</tr>
<tr>
<td>Hepatitis B surface antigen-positive†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>Present</td>
<td>1.04 (0.61–1.77)</td>
<td>0.98 (0.57–1.69)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>Non-black</td>
<td>2.14 (1.67–2.75)</td>
<td>2.12 (1.65–2.72)</td>
</tr>
<tr>
<td>HIV viremia copy-years (log copy-years/mL)†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;2</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>2–6</td>
<td>1.37 (0.67–2.77)</td>
<td>1.64 (0.84–3.23)</td>
</tr>
<tr>
<td>≥6</td>
<td>2.01 (0.66–6.12)</td>
<td>2.06 (0.69–6.10)</td>
</tr>
<tr>
<td>Pre-antiretroviral therapy CD4 count (cells/mm³)†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥200</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>&lt;200</td>
<td>1.22 (0.95–1.56)</td>
<td>1.17 (CI, 0.91–1.49)</td>
</tr>
</tbody>
</table>

Abbreviations: CI=confidence interval; HCV=hepatitis C virus; HIV=human immunodeficiency virus; HR=hazard ratio

* Hazard ratios adjusted for all other risk factors as well as history of alcohol dependence/abuse, history of injection/non-injection drug use, age, serum creatinine, and VA center patient volume.

† Diabetes mellitus, hepatitis B surface antigen status, and HIV RNA level were evaluated as time-varying covariates.
† CD4 T lymphocyte count measured within 180 days prior to initiation of antiretroviral therapy.